Primary Cells Market To Reach US$4.1 Billion By 2033 Astute Analytica

(MENAFN- GlobeNewsWire - Nasdaq) The market is undergoing robust expansion, driven by advancements in cell-based research and a paradigm shift towards more predictive, human-relevant models in drug development, regenerative medicine, and personalized therapeutic strategies.

Chicago, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The global primary cells market was valued at US$ 1.9 billion in 2024 and is anticipated to reach US$ 4.1 billion by 2033, growing at a CAGR of 10.6% during the forecast period 2025–2033.

Substantial government and private funding for biomedical research creates the foundational demand for primary cells. The US National Institutes of Health (NIH) allocated a significant budget of over $2.1 billion for stem cell research in fiscal year 2024. In Europe, UK Research and Innovation (UKRI) committed over £800 million to bioscience research projects during the same year. These large-scale investments directly translate into laboratory activity and consumption of critical cellular materials, underpinning the entire primary cells market.

Request Sample Pages:

Specific research initiatives further amplify demand within the market. California's Institute for Regenerative Medicine (CIRM) funded 45 new projects with over $150 million in 2024. Scientific output reflects this activity, with over 25,000 peer-reviewed publications citing primary human cell use in 2024. Disease-specific research is also a major driver; over 1,200 new grants for Alzheimer's modeling using primary neurons were awarded globally. Furthermore, global funding for rare disease research surpassed $10 billion in 2024, while active projects using primary immune cells for vaccine development reached over 3,000 in early 2025.

Key Findings in Primary Cells Market

Market Forecast (2033)	US$ 4.1 billion
CAGR	10.6%
Largest Region (2024)	North America (52%)
By Source	Human Source (71%)
By Type	Hematopoietic (Fastest CAGR)
By Application	ADME Toxicology Testing (62%)
By End Users	Pharmaceutical & Biotechnology Companies (Fastest CAGR)
Top Drivers	Growing demand for personalized medicine and targeted therapies. Advantages of primary cells over cell lines and animal models. Increased government funding and private investment in cell-based research.
Top Trends	Rising adoption of 3D cell culture and organ-on-a-chip technologies. Expanding applications in regenerative medicine and stem cell therapies. Increasing use of primary cells in developing novel cancer immunotherapies.
Top Challenges	High cost and limited availability of specific primary cell types. Short lifespan and finite proliferation of primary cells in culture. Ethical considerations and regulatory complexities in sourcing human tissues.

Cell and Gene Therapies Propel Unprecedented Demand for GMP-Grade Cells

The explosive growth of the cell and gene therapy pipeline represents the single largest demand driver for the primary cells market. The number of active cell therapy clinical trials worldwide surged past 1,500 in early 2025. This intense clinical activity is supported by a favorable regulatory environment. The FDA granted over 80 new Regenerative Medicine Advanced Therapy (RMAT) designations in 2024, accelerating development timelines. Patient access is also expanding, with the number of approved cell and gene therapies reaching 35 globally by the end of 2024.

The sheer scale of manufacturing required for these therapies creates enormous demand. Over 15,000 patients were enrolled in CAR-T therapy clinical trials globally in 2024. Each treatment requires immense cellular input; the average therapeutic dose in 2025 necessitates processing over 1 billion starting cells. To meet this need in the primary cells market, global biomanufacturing capacity expanded to a volume capable of treating 100,000 patients in 2024. The pipeline remains robust, with the number of new Investigational New Drug (IND) applications for cell-based therapies surpassing 150 in 2024.

Pharmaceutical Drug Discovery Shifts to More Predictive Primary Cell Models

The pharmaceutical industry's imperative to improve clinical trial success rates has cemented primary cells as the new gold standard. In 2024, more than 300,000 unique chemical compounds were screened against primary human hepatocytes for liver toxicity. The predictive power of these models is generating tangible results. The use of primary cell-based cardiotoxicity assays prevented an estimated 200 drug candidates with heart risks from entering clinical trials in 2024. This shift is now widespread in the primary cells market.

Adoption of these advanced models is accelerating. Over 5,000 pharmaceutical and biotech labs globally adopted primary cell-based assays for ADME-Tox screening in 2024. The complexity of these screens is also increasing, with the number of data points generated per high-content experiment surpassing 10,000. Efficacy testing is another major application, with over 1 million individual primary cell-based assays conducted for oncology drug screening. This activity is backed by significant investment, as pharmaceutical companies allocated over $4.5 billion to acquire advanced in-vitro models in 2024, and over 2,000 new drug discovery programs specified primary cell use in their protocols.

Advanced 3D Culture and Organoid Systems Redefine In-Vitro Research Across Global Primary Cells Market

The transition from two-dimensional cell layers to three-dimensional cultures that better mimic human tissue is revolutionizing research. The number of commercially available, validated organoid models derived from primary cells exceeded 400 in 2024. Cancer research is a major beneficiary of this technology. Over 50,000 new patient-derived organoid cultures were established for oncology studies in 2024. This trend is creating entirely new revenue streams within the primary cells market.

The ecosystem supporting 3D culture is expanding rapidly. Global shipments of 3D cell culture plates and scaffolds surpassed 10 million units in 2024. The scientific community is embracing these models, with over 3,000 research publications in 2024 featuring organ-on-a-chip technology using primary cells. Pharmaceutical adoption is also becoming mainstream, with over 200 companies establishing internal organoid-based screening platforms as of early 2025. Innovation continues, as more than 50 new biotech startups focused on novel 3D primary cell models were founded in 2024, and the number of human tissue types successfully modeled with organoids reached over 30 by 2025.

Enabling Technologies and Automation Scale Primary Cell Experimental Throughput

Technological advancements are making complex primary cell experiments more accessible and scalable. The installed base of automated cell isolation and sorting instruments in research labs grew by 3,000 units in 2024. This automation extends throughout the workflow. The number of automated liquid handling workstations configured for cell-based assays is projected to exceed 75,000 units globally by 2025. These tools are critical for managing the growing complexity of the primary cells market.

Analytical instrumentation is also becoming more sophisticated. Over 1,000 new high-content imaging systems were installed in 2024 for deep phenotypic analysis of primary cell cultures. At the genomic level, the number of single-cell sequencing experiments performed on primary cells surpassed 50,000 in 2024. Basic laboratory tools are also seeing high adoption, with global sales of live-cell imaging systems exceeding 4,000 units and the number of labs adopting automated cell counters growing by 10,000 in 2024. The market for consumables is likewise expanding, with over 200 new formulations of specialized primary cell culture media launched.

Regulatory Tailwinds and Animal Model Reduction Mandate Human Cell Use

A global regulatory shift away from animal testing is creating a powerful, long-term demand driver for the primary cells market. The FDA Modernization Act 2.0 directly spurred over 50 new drug applications in 2024 that used primary cell data in place of some animal studies. The European Union's Horizon Europe program similarly funded 75 new projects in 2024 to develop animal-free testing methods. These initiatives are having a measurable impact, as the number of in vivo toxicology studies on mammals was reduced by an estimated 1.2 million globally in 2024.

This regulatory acceptance is solidifying the role of primary cells in safety assessment. The number of qualified organ-on-a-chip platforms accepted by regulatory bodies for specific contexts of use reached 20 in 2025. The EPA's Endocrine Disruptor Screening Program accepted data from over 15 different primary cell-based assays in 2024. Industry is responding proactively, with over 300 companies formally committing to the 3Rs principles in their 2024 corporate reports. To ensure consistency, the number of inter-agency validation studies for new primary cell-based test methods reached 40 across primary cells market in 2024.

Massive Corporate Investment and Financial Activity Signal Strong Market Confidence

The financial community has recognized the immense growth potential of the primary cells market . Venture capital funding for cell therapy and regenerative medicine companies soared past $18 billion in 2024. This enthusiasm is mirrored in public markets, which saw over 15 initial public offerings (IPOs) of biotech companies specializing in cell-based technologies. Private equity firms also participated heavily, investing over $5 billion in life science tools and diagnostics companies.

Corporate activity remains exceptionally strong. The number of merger and acquisition (M&A) deals involving cell culture technology companies surpassed 60 in 2024. Strategic partnerships between large pharma and primary cell technology providers exceeded 100 in the same year, highlighting the value of innovation. Investment is also flowing into infrastructure, with over $9 billion dedicated to new biomanufacturing and cell processing facilities. Even early-stage companies are thriving, as startups focused on AI-driven cell analysis and phenotyping raised over $500 million in seed and Series A funding.

Customize the Data Scope to Match Your Objectives:

Sophisticated Bio-Infrastructure and Sourcing Underpin the Market Supply Chain

A complex and growing infrastructure is essential to supply the primary cells market . Global biobanks distributed over 500,000 vials of cryopreserved primary cells for research in just the first half of 2025. This output is supported by over 40 new GMP-compliant cell processing and biobanking facilities commissioned globally in 2024. The supply chain relies on advanced technology, with the installed base of controlled-rate freezers growing by 5,000 units and over 2 million commercial cell shipments using real-time temperature monitoring. The capacity of global liquid nitrogen storage for biological samples now exceeds 1 billion vials. The foundation of this chain is ethical tissue sourcing. Over 1 million new patient samples were consented and added to research biobanks in 2024, with over 20,000 human tissues recovered for research. The number of registered donors in the US surpassed 150 million, supported by over 250 accredited tissue procurement organizations.

The market for primary human hepatocytes provides a clear example of this supply chain in action. Key players in the primary cells market are scaling to meet intense demand. Thermo Fisher Scientific expanded its portfolio in 2024 with 15 new donor lots and shipped cells to over 800 institutions. Lonza demonstrated its scale by manufacturing over 5,000 vials from a single donor lot, with each batch undergoing over 50 characterization assays. Sekisui XenoTech enhanced its inventory in 2025 with 25 new validated lots and provided hepatocytes from over 200 different human donors to its clients in 2024. Innovation continues at the product level, as Thermo Fisher Scientific launched a new medium in 2025 that extends hepatocyte viability by 48 hours, showcasing the competitive dynamics driving progress.

Global Primary Cells Market Key Players:

• AllCells
• Creative Bioarray
• Cureline
• American Type Culture Collection
• Axol Biosciences Ltd.
• Lonza Group, AG
• Cell Biologics, Inc.
• Thermo Fisher Scientific
• Merck KGaA
• PromoCell
• STEMCELL Technologies
• ZenBio
• Other Prominent Players

Key Market Segmentation:

By Source

• Animal Source
• Human Source

By Type

• Hematopoietic
• Hepatocytes
• Renal Cells
• Gastrointestinal Cells
• Skin Cells
• Lung Cells
• Other Types

By End Users

• Pharmaceutical & Biotechnology Companies
• Research Institutes

By Application

• ADME Toxicology Testing
• Other Applications

By Region

• Europe
• Asia Pacific
• Middle East & Africa (MEA)
• South America

Need a Detailed Walkthrough of the Report? Request a Live Session:

About Astute Analytica

Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.

With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.

Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: ...
Website:
Follow us on: LinkedIn | Twitter | YouTube

CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: ... Website:

MENAFN10092025004107003653ID1110043477